オメガ3処方薬の世界市場：市場規模・シェア・動向分析 (薬剤別・用途別・流通チャネル別・地域別・セグメント別、2025年～2030年)

オメガ3処方薬市場の成長と動向：

世界のオメガ3処方薬の市場規模は、2030年には18億米ドルに達すると予想され、2030年までにCAGR 4.90%で拡大する見込みです。

この業界の成長は、心血管疾患 (CVD) の症例の増加と食生活の変化に起因しています。血中トリグリセリド濃度の上昇は、心血管疾患のリスク上昇と関連することが知られています。2021年の欧州心臓病学会によると、毎年1,790万人がCVDで死亡しており、世界の死因の第1位となっています。さらに、医薬品への応用の可能性が広がっているため、業界参加者によるオメガ3ベースの医薬品の発売が成長を後押しすると予想されています。

例えば、2020年に米国FDAは、米国アマリン社製のオメガ3系医薬品VASCEPAについて、新たな心血管適応症とラベルの拡大を承認しました。中性脂肪の増加は動脈狭窄を引き起こし、心臓発作や脳卒中のリスクを高めます。膵臓の炎症である膵炎も、同様に極端に高い値から生じる可能性があります。トリグリセリドの値は、糖尿病や肥満の結果として上昇し、これは広く蔓延している問題です。アメリカの成人の平均25%は、血中アルコール濃度がボーダーラインで高いです。オメガ3脂肪酸の薬は、米国FDAが承認した500mg/dl以上のトリグリセリド値に対してのみ処方されます。オメガ3処方薬は、COVID-19の大流行時に大きな市場の動きを示しました。

これは、CVD患者の管理における重要な役割のためです。例えば、2021年8月、Woodward Pharma Services LLCはGlaxoSmithKlineからLOVAZAを買収したと発表しました。同社はさらに、消費者と医療提供者を教育し、同製品の採用を促進することを目指しています。さらに、トリグリセリドを低下させるための複数の研究開発研究が実施されています。トリグリセリド値の上昇に関する17の組織化された無作為化臨床試験から得られた知見を組み合わせて分析した結果、処方されたオメガ3脂肪酸薬によって20～30%値を低下させることができることが示唆されています。これにより、高い製品需要が見込まれます。

オメガ3処方薬市場：分析概要

• Lovazaは予測期間中、緩やかな成長機会が見込まれます。
• 心血管が市場を独占し、2024年には86.8%の最大収益シェアを占めています。
• 小売薬局が市場を独占し、その幅広いアクセスと消費者の利便性により、2024年には53.6%の最大収益シェアを占めています。
• オンライン薬局分野は、便利で利用しやすい医療ソリューションに対する消費者の嗜好の高まりにより、緩やかな成長が見込まれています。
• 北米は、2024年に42.9%のシェアで世界のオメガ3処方薬市場を独占し、予測期間中に大きく成長すると予測されています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 オメガ3処方薬市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• オメガ3処方薬市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 オメガ3処方薬市場：薬剤別の推定・動向分析

• セグメント別ダッシュボード
• オメガ3処方薬市場：薬剤別の変動分析
• オメガ3処方薬市場：薬剤別
• 市場規模の予測・動向分析 (2018～2030年)
• ヴァシェパ
• ロヴァザ
• その他

第5章 オメガ3処方薬市場：用途別の推定・動向分析

• セグメント別ダッシュボード
• オメガ3処方薬市場：用途別の変動分析
• オメガ3処方薬市場の展望：用途別
• 市場規模の予測・動向分析 (2018～2030年)
• 心血管
• その他

第6章 オメガ3処方薬市場：流通チャネル別の推定・動向分析

• セグメント別ダッシュボード
• オメガ3処方薬市場：流通チャネル別の変動分析
• オメガ3処方薬市場の展望：流通チャネル別
• 市場規模の予測・動向分析 (2018～2030年)
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 オメガ3処方薬市場：地域推定・動向分析

• 地域別のダッシュボード
• 市場規模の予測・動向分析 (2018～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 市場参入企業の分類
• 最近の動向と影響分析：主要な市場参入企業別
• 企業別の市場シェア分析 (2024年)
• 主要企業のプロファイル
  • Amarin Pharmaceuticals Ireland Limited
  • Woodward Pharma Services LLC
  • Mankind Pharma
  • GLW Pharma GMBH
  • CSPC Pharmaceutical Group Limited
  • Sofgen
  • WILSHIRE PHARMACEUTICALS, INC.
  • Sun Pharmaceutical Industries Ltd.
  • PuraCap Pharmaceutical LLC
  • ChartwellPharma
  • Amneal Pharmaceuticals LLC

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Omega 3 Prescription Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 6 Global Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 7 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 10 North America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 11 North America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 13 U.S. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 14 U.S. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 16 Canada Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 17 Canada Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Mexico Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 19 Mexico Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 20 Mexico Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 21 Europe Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 22 Europe Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 23 Europe Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 24 Europe Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 UK Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 26 UK Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 27 UK Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Germany Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 29 Germany Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 30 Germany America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 France Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 32 France Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 33 France Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Spain Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 35 Spain Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 36 Spain Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Italy Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 38 Italy Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 39 Italy Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Denmark Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 41 Denmark Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 42 Denmark Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Sweden Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 44 Sweden Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 45 Sweden Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Norway Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 47 Norway Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 48 Norway Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 China Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 54 China Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 55 China Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Japan Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 57 Japan Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 58 Japan Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 India Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 60 India Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 61 India Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 South Korea Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 63 South Korea Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 64 South Korea Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Australia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 66 Australia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 67 Australia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Thailand Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 69 Thailand Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 70 Thailand Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 71 Latin America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 72 Latin America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 73 Latin America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 74 Latin America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 Brazil Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 76 Brazil Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 77 Brazil Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 78 Argentina Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 79 Argentina Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 80 Argentina Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 81 MEA Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 82 MEA Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 83 MEA Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 84 MEA Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 85 South Africa Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 86 South Africa Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 87 South Africa Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 90 Saudi Arabia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 91 UAE Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 92 UAE Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 93 UAE Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 94 Kuwait Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 95 Kuwait Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 96 Kuwait Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research approaches
• Fig. 2 Value chain-based sizing & forecasting
• Fig. 3 Market formulation & validation
• Fig. 4 Omega 3 Prescription Drugs Market segmentation
• Fig. 5 Market driver analysis (current & future impact)
• Fig. 6 Market restraint analysis (current & future impact)
• Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 8 Porter's five forces analysis
• Fig. 9 Omega 3 Prescription Drugs Market: Drug outlook and key takeaways
• Fig. 10 Omega 3 Prescription Drugs Market: Drug movement analysis
• Fig. 11 Vascepa market, 2018 - 2030 (USD Million)
• Fig. 12 Lovaza market, 2018 - 2030 (USD Million)
• Fig. 13 Others market, 2018 - 2030 (USD Million)
• Fig. 14 Omega 3 Prescription Drugs Market: Application outlook and key takeaways
• Fig. 15 Omega 3 Prescription Drugs Market: Application movement analysis
• Fig. 16 Cardiovascular market, 2018 - 2030 (USD Million)
• Fig. 17 Others market, 2018 - 2030 (USD Million)
• Fig. 18 Omega 3 Prescription Drugs Market: Distribution channel outlook and key takeaways
• Fig. 19 Omega 3 Prescription Drugs Market: Distribution channel movement analysis
• Fig. 20 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 North America omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 U.S. omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Canada omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Mexico omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Europe omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 UK omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Germany omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 France omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Italy omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Spain omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Denmark omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Sweden omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Norway omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Asia Pacific omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Japan omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 China omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 India omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Australia omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Thailand omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 South Korea omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Latin America omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Brazil omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Argentina omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 MEA omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 South Africa omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Saudi Arabia omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UAE omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Kuwait omega 3 prescription drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 List of key emerging company's/disruptors/innovators

Omega 3 Prescription Drugs Market Growth & Trends:

The global omega 3 prescription drugs market size is expected to reach USD 1.80 billion in 2030 and is expected to expand at a CAGR of 4.90% by 2030. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.

Omega 3 Prescription Drugs Market Report Highlights:

• Lovaza is projected to experience moderate growth opportunities during the forecast period.
• Cardiovascular dominated the market and accounted for the largest revenue share of 86.8% in 2024
• Retail pharmacy dominated the market and accounted for the largest revenue share of 53.6% in 2024 due to its wide accessibility and consumer convenience
• The online pharmacy segment is expected to witness moderate growth due to the increasing consumer preference for convenient and accessible healthcare solutions
• North America dominated the global omega 3 prescription drugs market with a share of 42.9% in 2024 and is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional Scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Omega 3 Prescription Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
    • 3.2.1.2. Growing Awareness of Omega-3 Health Benefits
    • 3.2.1.3. Advancements in Pharmaceutical Formulations
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Prescription Omega-3 Drugs
    • 3.2.2.2. Regulatory and Reimbursement Challenges
• 3.3. Omega 3 Prescription Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Omega 3 Prescription Drugs Market: Drug Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Omega 3 Prescription Drugs Market: Drug Movement Analysis
• 4.3. Omega 3 Prescription Drugs Market by Drug (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Vascepa
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Lovaza
  • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Omega 3 Prescription Drugs Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Omega 3 Prescription Drugs Market: Application Movement Analysis
• 5.3. Omega 3 Prescription Drugs Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Cardiovascular
  • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Omega 3 Prescription Drugs Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
• 6.3. Omega 3 Prescription Drugs Market by Distribution Channel Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospital Pharmacy
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Retail Pharmacy
  • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Online Pharmacy
  • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Omega 3 Prescription Drugs Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Recent Developments & Impact Analysis by Key Market Participants
• 8.3. Company Market Share Analysis, 2024
• 8.4. Key Company Profiles
  • 8.4.1. Amarin Pharmaceuticals Ireland Limited
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Woodward Pharma Services LLC
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Mankind Pharma
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. GLW Pharma GMBH
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. CSPC Pharmaceutical Group Limited
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Sofgen
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. WILSHIRE PHARMACEUTICALS, INC.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Sun Pharmaceutical Industries Ltd.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. PuraCap Pharmaceutical LLC
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. ChartwellPharma
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Amneal Pharmaceuticals LLC
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives